Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first lin ...
Trustvare Introduces Secure And Efficient PST To MSG Conversion Software. February 18, 2026 12:17 am - TrustVare is announcing the release of its Secure and Efficient PST to MSG Conversion Software.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results